Hypoxia, drug therapy and toxicity

Pharmacology and Therapeutics

Volumn 113, Issue 2, 2007, Pages 229-246

  Lee, KangAe ^a,b   Roth, Robert A ^b,c   LaPres, John J ^a,b  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Drug design and toxicity; Factor inhibiting HIF; Hypoxia; Hypoxia inducible factor 1; Prolyl hydroxylase domain containing proteins

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; APIGENIN; AXITINIB; BERBERINE; BEVACIZUMAB; BORTEZOMIB; DIBENZOYLMETHANE DERIVATIVE; ECHINOMYCIN; ERLOTINIB; FG 4095; FLAVOPIRIDOL; GEFITINIB; GELDANAMYCIN; GROWTH FACTOR; HYPERICIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IRINOTECAN; KIN 847; KS 119; LONAFARNIB; PX 478; RADICICOL; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRASTUZUMAB; TRICHOSTATIN A; TX 402; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINCRISTINE;

ADAPTATION; ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CELL DEATH; CELL HYPOXIA; CYTOTOXICITY; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; HYDROXYLATION; HYPOXIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; STROKE; TISSUE OXYGENATION;

ANIMALS; ANOXIA; CELL DEATH; CELL HYPOXIA; DRUG THERAPY; DRUG TOXICITY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEURONS; SIGNAL TRANSDUCTION;

EID: 33846415800     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.08.001     Document Type: Review

References (161)

1. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature 392 (1998) 405-408
2. Arteel G.E., Iimuro Y., Yin M., Raleigh J.A., and Thurman R.G. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 25 (1997) 920-926
3. Asikainen T.M., Schneider B.K., Waleh N.S., Clyman R.I., Ho W.B., Flippin L.A., et al. Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung. Proc Natl Acad Sci USA 102 (2005) 10212-10217
4. Azarbayjani F., and Danielsson B.R. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs?. Epilepsia 43 (2002) 457-468
5. Bacon J., Cramer C., Petrella D., Sun E., and Ulrich R. Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Toxicology 108 (1996) 9-16
6. Beck I., Ramirez S., Weinmann R., and Caro J. Enhancer element at the 3′-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem 266 (1991) 15563-15566
7. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22 (2003) 4082-4090
8. Briere J., Favier J., Benit P., Ghouzzi V., Lorenzato A., Rabier D., et al. Mitochondrial succinate is instrumental for HIF1a nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet 14 (2005) 3263-3269
9. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58 (1998) 1408-1416
10. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
11. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1 (2005) 409-414
12. Bunn H.F., and Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76 (1996) 839-880
13. Burke B., Giannoudis A., Corke K.P., Gill D., Wells M., Ziegler-Heitbrock L., et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163 (2003) 1233-1243
14. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
15. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., and Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95 (1998) 11715-11720
16. 2 sensing. J Biol Chem 275 (2000) 25130-25138
17. Chandel N.S., and Schumacker P.T. Cellular oxygen sensing by mitochondria: old question and new insight. J Appl Physiol 88 (2000) 1880-1889
18. Chen C., Pore N., Behrooz A., Ismail-Beigi F., and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276 (2001) 9519-9525
19. Chowdhury G., Kotandeniya D., Daniels J.S., Barnes C.L., and Gates K.S. Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. Chem Res Toxicol 17 (2004) 1399-1405
20. Cioffi C.L., QinLiu X., Kosinski P.A., Garay M., and Bowen B.R. Differential regulation of HIF-1alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun 303 (2003) 947-953
21. Coelho A., Ferraz A., Neto R., Souza A., and Ferraz E. Subdiaphragmatic venous stasis and tissular hypoperfusion as source of metabolic acidosis during passive portal-jugular and cacal-jugular bypasses in dogs. Acta Cir Bras (2000) 15
22. Coleman C.N., Mitchell J.B., and Camphausen K. Tumor hypoxia: chicken, egg, or a piece of the farm?. J Clin Oncol 20 (2001) 610-615
23. Copple B., Rondelli C., Maddox J., Hoglen N., Ganey P., and Roth R. Modes of cell death in rat liver after monocrotaline exposure. Toxicol Sci 77 (2004) 172-182
24. Copple B.L., Roth R.A., and Ganey P.E. Anticoagulation and inhibition of nitric oxide synthase influence hepatic hypoxia after monocrotaline exposure. Toxicol 225 (2006) 128-137
25. Cowen R.L., Williams K.J., Chinje E.C., Jaffar M., Sheppard F.C.D., Telfer B.A., et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64 (2004) 1396-1402
26. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
27. Cusack B.J., Crowley J.J., Mercer G.D., Charan N.B., and Vestal R.E. Theophylline clearance in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia. Am Rev Respir Dis 133 (1986) 1110-1114
28. Dahia P.L.M., Ross K.N., Wright M.E., Hayashida C.Y., Santagata S., Barontini M., et al. A HIF1-alpha; regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1 (2005) e8
29. Danielsson B., Skold A.C., Azarbayjani F., Ohman I., and Webster W. Pharmacokinetic data support pharmacologically Induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol Appl Pharmacol 163 (2000) 164-175
30. Danielsson B.R., Skold A.C., Johansson A., Dillner B., and Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 193 (2003) 168-176
31. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., and Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1α. Cancer Res 66 (2006) 3688-3698
32. Demougeot C., Van Hoecke M., Bertrand N., Prigent-Tessier A., Mossiat C., Beley A., et al. Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2′-Dipyridyl in the rat photothrombotic ischemic stroke model. J Pharmacol Exp Ther 311 (2004) 1080-1087
33. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., et al. Investigating hypoxia tumor physiology through gene expression pattern. Oncogen 22 (2003) 5907-5914
34. Duong T.Q., and Kim S.G. Quantitative MR measurements of interstitial oxygen tension in intact rat brain; hyperoxia and hypercapnia. Proc Int Soc Magn Reson Med 8 (2000) 440
35. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
36. Erez N., Stambolsky P., Shats I., Milyavsky M., Kachko T., and Rotter V. Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. FEBS Lett 567 (2004) 311-315
37. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19 (2005) 342-353
38. Ferrara N. Molecular and biochemical properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
39. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3 (2005) 11-16
40. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Disc 3 (2004) 391-400
41. Fisher T.S., Etages S.D., Hayes L., Crimin K., and Li B. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J Biol Chem 280 (2005) 17749-17757
42. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
43. Fradette C., and Du Souich P. Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5 (2004) 257-271
44. Ganey P.E., Luyendyk J.P., Maddox J.F., and Roth R.A. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Int 150 (2004) 35-51
45. Gardner L.B., Li Q., Park M.S., Flanagan W.M., Semenza G.L., and Dang C.V. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276 (2001) 7919-7926
46. Gavalakis J., du Souich P., and Sharkawi M. Acute moderate hypoxia reduces ethanol elimination in the conscious rabbit. Toxicology 137 (1999) 109-116
47. Geoerger B., Kerr K., Tang C.B., Fung K.M., Powell B., Sutton L.N., et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61 (2001) 1527-1532
48. Goldberg M.A., Dunning S.P., and Bunn H.F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242 (1988) 1412-1415
49. Gong Y., and Agani F.H. Oligimycin inhibits HIF1 α expression in hypoxic tumor cells. Am J Physiol Cell Physiol 288 (2005) 1023-1029
50. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
51. Gregus Z., and Klaassen C. Mechanisms of toxicity. In: Klaassen C.D. (Ed). Cassarett and Doull's Toxicology: The Basic Science of Poisons. (6th edition) (2001), McGraw-Hill, New York 59
52. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1 (2005) 401-408
53. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and oxygen sensing. Cell Metab 1 (2005) 401-408
54. Harris A.L. Hypoxia - a key regulatory factor in tumor growth. Nature Rev Cancer 2 (2002) 38-47
55. Hockel M., and Vaupel P. Tumor Hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 98 (2001) 266-276
56. Hogenesch J.B., Han W.C., Jackiw V.H., Brown R.C., Gu Y.Z., Pray-Grant M., et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interact with components of the dioxin signaling pathway. J Biol Chem 272 (1997) 8581-8593
57. Huang Z.J., Edery I., and Rosbash M. PAS is a dimerization domain common to drosophila period and several transcription factors. Nature 364 (1993) 259-262
58. Ibrahim N.O., Hahn T., Franke C., Stiehl D.P., Wirthner R., Wenger R.H., et al. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res 65 (2005) 11094-11100
59. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 (2002) 19944-29936
60. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8 (2005) 143-153
61. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
62. James L.P., Donahower B., Burke A.S., McCullough S., and Hinson J.A. Induction of the nuclear factor HIF-1alpha in acetaminophen toxicity: evidence for oxidative stress. Biochem Biophys Res Commun 343 (2006) 171-176
63. James P.E., Madhani M., Roebuck W., Jackson S.K., and Swartz H.M. Endotoxin-induced liver hypoxia: defective oxygen delivery versus oxygen consumption. Nitric Oxide 6 (2002) 18-28
64. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., et al. Regulation and destabilization of HIF-1α by ARD-mediated acetylation. Cell 111 (2002) 709-720
65. 2 in liver using EPR oximetry. J Appl Physiol 80 (1996) 552-558
66. Kasper L.H., Boussouar F., Boyd K., Xu W., Biesen M., Rehg J., et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J 24 (2005) 3846-3858
67. 2 and blood flow in the human skeletal muscle. Arch Orthop Trauma Surg 107 (1988) 114-116
68. Kim J.-w., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
69. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65 (2005) 9047-9055
70. Kung A.L., Zabludoff S.Z., France D.S., Freedman S.J., Tanner E.A., Vieira A., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
71. Kunz M., Ibrahim S., Koczan D., Thiesen H.J., Koehler H.J., Akcer T., et al. Activation of c-jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ 12 (2001) 137-145
72. Laderoute K., Wardman P., and Rauth A.M. Molecular mechanisms for the hypoxiadependent activation of 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233). Biochem Pharmacol 37 (1988) 1487-1495
73. Land S.C. Oxygen sensing pathway and the development of mammalian gas exchange. Redox Rep 8 (2003) 325-340
74. Lando D. Asparagine hydroxylation of the HIF transactivation domain a hypoxia switch. Science 295 (2002) 856-861
75. LaPres J.J., Glover E., Dunham E.E., Bunger M.K., and Bradfield C.A. ARA9 modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor. J Biol Chem 275 (2000) 6153-6159
76. Lee Y.M., Jeong C.H., Koo S.Y., Son M.J., Song H.S., Bae S.K., et al. Determination of hypoxic region by hypoxic markerin developing mouse embryo in vivo: a possible signal for vessel development. Dev Dyn 220 (2001) 175-186
77. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., et al. Evaluating hypoxia-inducible factor-1{alpha} as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65 (2005) 7249-7258
78. Liu J., Narasimhan P., Yu F., and Chan P.H. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 36 (2005) 1264-1269
79. Lu H., Forbes R.A., and Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277 (2002) 23111-23115
80. Luyendyk J., Maddox J., Cosma G., Ganey P., Cockerell G., and Ra R. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 307 (2003) 9-16
81. Luyendyk J.P., Lehman-McKeeman L.D., Nelson D.M., Bhaskaran V.M., Reilly T.P., Car B.D., et al. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: comparison with famotidine. Toxicol Sci 90 (2006) 569-585
82. Luyendyk J.P., Maddox J.F., Green C.D., Ganey P.E., and Roth R.A. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 40 6 (2004) 1342-1351
83. Luyendyk J.P., Shaw P.J., Green C.D., Maddox J.F., Ganey P.E., and Roth R.A. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 414 (2005) 1023-1031
84. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62 (2002) 2478-2482
85. Mabjeesh N.J., Willard M.T., Harris W.B., Sun H.-Y., Wang R., Zhong H., et al. Dibenzoylmethane, a natural dietary compound, induces HIF-1[alpha] and increases expression of VEGF. Biochem Biophys Res Co 303 (2003) 279-286
86. Macpherson G.R., and Figg W.D. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol Ther 3 (2004) 503-504
87. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interact with HIF-1 α and VHL to mediate repression of HIF-1 transcriptional activity. Gene Dev 15 (2001) 2675-2686
88. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacker P.T., et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 1 (2005) 393-399
89. Marti H.H., Jung H.H., Pfeilschifter J., and Bauer C. Hypoxia and cobalt stimulate lactate dehydrogenase (LDH) activity in vascular smooth muscle cells. Pflugers Arch 429 (1994) 216-222
90. Massieu L., Gomez-Roman N., and Montiel T. In vivo potentiation of glutamate-mediated neuronal damage after chronic administration of the glycolysis inhibitor iodoacetate. Exp Neurol 165 (2000) 257-267
91. Millicovsky G., and Johnston M.C. Maternal hyperoxia greatly reduces the incidence of phenytoin-induced cleft lip and palate in A/J mice. Science 212 (1981) 671-672
92. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460 (1999) 251-256
93. Mizukami Y., Jo W.-S., Duerr E.-M., Gala M., Li J., Zhang X., et al. Induction of interleukin-8 preserves the angiogenic response in HIF1 α-deficiency colon cancer cells. Nat Med 9 (2005) 992-997
94. Mu D., Chang Y.S., Vexler Z.S., and Ferriero D.M. Hypoxia-inducible factor 1a and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 195 (2005) 407-415
95. Nies A., Shand D., and Wilkinson G. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1 (1976) 135-155
96. Osada M., Imaoka S., and Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett 575 (2004) 59-63
97. Papadopoulou M.V., and Bloomer W.D. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 9 (2003) 5714-5720
98. Piret J.P., Motter D., Raes M., and Michiels C. Is HIF-1a a pro-or an anti-apoptotic protein?. Biochem Pharmacol 64 (2002) 889-892
99. 2 measured in vivo. J Appl Physiol 79 (1995) 2050-2057
100. Primeau A.J., Rendon A., Hedley D., Lilge L., and Tannock I.F. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11 (2005) 8782-8788
101. Pugh C.W., Tan C.C., Jones R.W., and Ratcliffe P.J. Functional analysis of an oxygen regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc Natl Acad Sci USA 88 (1991) 10553-10557
102. Richard D.E., Berra E., Gothie E., Roux D., and Poussegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-induced factor 1 α and enhance the transcriptional activity of HIF-1. J Biol Chem 274 (1999) 32631-32637
103. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., and Van Waes C. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1{alpha}, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10 (2004) 8665-8673
104. Riddick D.S., Lee C., Ramji S., Chinje E.C., Cowen R.L., Williams K.J., et al. Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33 (2005) 1083-1096
105. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9 (2002) 36-44
106. Roth R., and Rubin R. Comparison of the effect of carbon monoxide and of hypoxic hypoxia. I. In vivo metabolism, distribution and action of hexobarbital. J Pharmacol Exp Ther 199 (1976) 53-60
107. Roth R., and Rubin R. Role of blood flow in carbon monoxide-and hypoxic hypoxia-induced alterations in hexobarbital metabolism in rats. Drug Metab Dispos 4 (1976) 460-467
108. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Chang H., et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63 (2003) 5978-5991
109. Ruscher K., Freyer D., Karsch M., Isaev N., Megow D., Sawitzki B., et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22 (2002) 10291-10301
110. Sabia P.J., Powers E.R., Ragosta M., Sarembock I.J., Burwell L.R., and Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infaction. N Engl J Med 327 (1992) 1825-1831
111. Salnikow K., Davidson T., and Costa M. The role of hypoxia-inducible signaling pathway in nickel carcinogenesis. Environ Health Perspect 110 Suppl 5 (2002) 831-834
112. Salnikow K., Donald S.P., Bruick R.K., Zhitkovich A., Phang J.M., and Kasprzak K.S. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 279 (2004) 40337-40344
113. Salnikow K., Su W., Blagosklonny M.V., and Costa M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res 60 (2000) 3375-3378
114. Sang N., Stiehl D.P., Bohensky J., Leshchinsky V., and Srinivas J.C. MAPK signaling up-regulated the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278 (2003) 14013-14019
115. Schultz A., Lavie L., Hochberg I., Beyar R., Stone T., Skorecki K., et al. Inter-individual heterogeneity in the hypoxia regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100 (1999) 547-552
116. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-[alpha] prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
117. 2 homeostasis. Curr Opin Genet Dev 8 (1998) 588-594
118. Semenza G.L. HIF1: mediator of physiological and pathophysiological response to hypoxia. J Appl Physiol 88 (2000) 1474-1480
119. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature 3 (2003) 721-731
120. Semenza G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19 (2004) 176-182
121. Semenza G.L. HIF1 and human disease: one highly involved factor. Genes Dev 14 (2006) 1983-1991
122. Seow H.A., Penketh P.G., Shyam K., Rockwell S., and Sartorelli A.C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA 102 (2005) 9282-9287
123. Shannon D.J., Condron C.M., and Toomey D. Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29 (2003) 297-307
124. Shen E.S., Garry V.F., and Anders M.W. Effect of hypoxia on carbon tetrachloride hepatotoxicity. Biochem Pharmacol 31 (1982) 3787-3793
125. Shibata T., Giaccia A.J., and Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4 (2002) 40-48
126. Shibayama Y. Enhanced hepatotoxicity of endotoxin by hypoxia. Pathol Res Pract 182 (1987) 390-395
127. Shimizu S., Eguchi Y., Kamiike W., Itoh Y., Hasegawa J., Yamabe K., et al. The role of oxygen tension in the regulation of embryonic lung development. J Pediatr Surg 40 (2005) 32-35
128. Shinkai T., Shinkai M., Pirker M.A., Montedonico S., and Puri P. The role of oxygen tension in the regulation of embryonic lung development. J Pediatr Surg 40 (2005) 32-35
129. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
130. Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nerve system. J Biol Chem 280 (2005) 41732-41743
131. Sonna L.A., Cullivan M.L., Sheldon H.K., Pratt R.E., and Lilly C.M. Effect of hypoxia on gene expression by human hepatocytes (HepG2). Physiol Genom 12 (2003) 195-207
132. Sotaniemi E., Arvela P., and Huhti E. Increased clearance of tolbutamide from the blood of asthmatic patients. Ann Allergy 29 (1971) 139-141
133. Sotaniemi E., Arvela P., Huhti E., and Koivisto O. Half-life of tolbutamide in patients with chronic respiratory failure. Eur J Clin Pharmacol 4 (1971) 29-31
134. Stolze I.P., Tian Y.-M., Appelhoff R.J., Turley H., Wykoff C.C., Gleadle J.M., et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 279 (2004) 42719-42725
135. Su H., Arakawa-Hoyt J., and Kan Y.W. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 99 (2002) 9480-9485
136. Tacchini L., Fusar-Poli D., and Bernelli-Zazzera A. Activation of transcription factors by drugs inducing oxidative stress in rat liver. Biochem Pharmacol 63 (2002) 139-148
137. Tan C., De Noronha R.G., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65 (2005) 605-612
138. Teicher B.A. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9 (1995) 475-506
139. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
140. Thurman R.G. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275 (1998) G605-G611
141. Thurman R.G., Bradford B.U., Iimuro Y., Frankenberg M.V., Knecht K.T., Connor H.D., et al. Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Front Biosci 4 (1999) e42-e46
142. Tsuzuki Y., Fukumura D., Oosthuyse B., Koike C., Carmeliet P., and Jain R.K. Vasculae endothelial growth factor (VEGF) modulatin by targeting Hypoxia-Inducible Factor-1a→Hypoxia Response Element→VEGF cascade. Differentially regulates vascular reponse and growth rate in tumors. Cancer Res 60 (2000) 6248-6252
143. Tuckerman J.R., Zhao Y., Hewitson K.S., Tian Y.-M., Pugh C.W., Ratcliffe P.J., et al. Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS Lett 576 (2004) 145-150
144. Tuyl M., Liu J., Wang J., Kuliszewski M., Tibboel D., and Post M. Role of oxygen and vascular development in epitherlial branching morphogenesis of the developing mouse lung. Am J Physiol Lung Cell Mol Physiol 288 (2005) 167-178
145. Varin F., and Huet P.M. Hepatic microcirculation in the perfused cirrhotic rat liver. J Clin Invest 76 (1985) 1904-1912
146. Vengellur A., and LaPres J.J. The role of hypoxia inducible factor α in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci 82 (2004) 638-646
147. Vengellur A., Phillips J.M., Hogenesch J.B., and LaPres J.J. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells. Phys Genom 22 (2005) 308-318
148. Vengellur A., Woods B.G., Ryan H.E., Johnson R.S., and LaPres J.J. Gene expression profiling of the hypoxia signaling pathway in hypoxia inducible factor 1α null mouse embryonic fibroblasts. Gene Exp 11 (2003) 181-197
149. Verna McErlane A.Y., McCarthy H.O., Hughes C.M., Patterson L.H., Hirst D.G., Robson T., et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 7 (2005) 851-859
150. 2 tension. Proc Natl Acad Sci USA 92 (1995) 5510-5514
151. Wang W.-d., Chen Z.-t., Li R., Li D.-z., Duan Y.-z., Cao Z.-h., et al. Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements. Cancer Sci 96 (2005) 918-924
152. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
153. Weber A., Dzietko M., Berns M., Felderhoff-Mueser U., Heinemann U., Maier R.F., et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 20 (2005) 594-600
154. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molec Cancer Therap 3 (2004) 233-244
155. Wick A., Wick W., Waltenberger J., Weller M., Dichgans J., and Schulz J.B. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22 (2002) 6401-6407
156. Yao K., Gietema J.S., Hida eS., Selvakumaran M., Fonrose X., Haas N., et al. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer 93 (2005) 1356-1363
157. Yu A.Y., Frid M.G., Shimoda L.A., Wiener C.M., Stenmark K., and Semenza G.L. Temporal, spatial and oxygen-regulated expression of hypoxia-inducible factor 1 in the lung. Am J Physiol 275 (1998) L818-L826
158. Yu A.Y., Shimoda L.A., Iyer N.V., Huso D.L., Sun X., McWilliams R., et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1a. J Clin Invest 103 (1999) 691-696
159. Yuan J., Narayanan L., Rockwell S., and Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60 (2000) 4372-4376
160. Yue X., and Tomanek R.J. Stimulation of coronary vasculogenesis/angiogenesis by hypoxia in cultured embryonic heart. Dev Dyn 216 (1999) 28-36
161. Zaman K., Ryu H., Hall D., O'Donovan K., Lin K.-I., Miller M.P., et al. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible Factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21waf1/cip1, and erythropoietin. J Neurosci 19 (1999) 9821-9830